Published in
American Society of Hematology, Blood, 3(131), p. 289-300, 2018
DOI: 10.1182/blood-2017-04-778829
Links
Tools
Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia
Journal article published in 2017 by
Arnaud Petit 
,
Amélie Trinquand,
Sylvie Chevret,
Paola Ballerini,
Jean-Michel Cayuela,
Nathalie Grardel,
Aurore Touzart ,
Benoit Brethon,
Hélène Lapillonne,
Claudine Schmitt,
Sandrine Thouvenin,
Gerard Michel,
Claude Preudhomme,
Jean Soulier,
Judith Landman-Parker
and other authors.
,
Amélie Trinquand,
Sylvie Chevret,
Paola Ballerini,
Jean-Michel Cayuela,
Nathalie Grardel,
Aurore Touzart ,
Benoit Brethon,
Hélène Lapillonne,
Claudine Schmitt,
Sandrine Thouvenin,
Gerard Michel,
Claude Preudhomme,
Jean Soulier,
Judith Landman-Parker
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points In pediatric T-ALL, oncogenetic markers, MRD, and WBC count are independent predictors of outcome. These factors should be used together for individual treatment stratification.